ECR has also divested its interest in non-core products like Hylase and Orbivan.
Hylase was divested for a one-time payment in January while Orbivan for $500,000 over two payments in March and an ongoing royalty stream.
ECR Pharmaceuticals president and CEO Cameron Durrant said that the company is executing against a clear strategy, part of which includes divesting or partnering non-core assets,while rigorously focusing on key assets, such as Bupap, Tussicaps, Zolpimist and Dexpak.